This study looked at whether high or low body mass index (BMI) influenced survival in people taking tyrosine kinase inhibitors (TKIs) as their first treatment after nephrectomy for advanced kidney cancer.
There were 235 patients with kidney cancer that had spread (metastatic) and who were reviewed in the study. All patients received first-line TKI as therapy. The relationship between BMI (low and high) and control of the disease was looked at. Patients in the low BMI group had a significantly lower control of their disease, whereas patients in the high BMI group had a significantly higher disease control. The analyses showed that low BMI indicated poor outcomes, whereas high BMI indicated favourable outcomes.